Panoramic: Automotive and Mobility 2025
Life Sciences and Health Care Venture Capital Investors
The life sciences and health care industry is advancing at record pace. Cell and gene therapies, AI, wearable devices, telemedicine and virtual care, are just a few examples of innovation.
Whether providing seed funding to startups, growth capital to early-stage companies, or financing buyouts, venture capital funding plays a critical role in sustaining the life sciences ecosystem.
Our global team of venture capital lawyers advise venture capital funds, life sciences companies with a captive venture fund, as well as universities and other academic research institutions. We provide multidisciplinary advice throughout the "venture capital lifecycle from company formation through fundraising and investments to eventual exit.
Regulation is simply a reality of doing business in this industry. Our venture capital lawyers regularly access our world-renowned global regulatory team to perform due diligence investigations of regulatory issues and risk factors, including the relevant approval pathway and reimbursement strategy for your product. We also serve as special regulatory counsel to issuers and underwriters in conjunction with initial public offerings and follow-on offerings.
Many of our team members have in-depth experience in industry and government, including at the FDA and other key regulatory agencies, and hold advance degrees in relevant disciplines.
Our capabilities at a glance
00
+
Judicial review wins
2
Ex-government policy advisors
00
+
Pieces of legislation changed
Hear from our clients and industry leaders
The whole team is super smart. They are all really easy to work with and then know our business inside out. They come to us proactively with issues and are incredibly responsive.
Chambers & Partners, UK Guide, 2025
An intellectually brilliant and commercially astute public law team. One of the very best in the city.
Chambers & Partners UK 2025
Hogan Lovells has a high capability in solving complex issues that involve both legal and technical perspectives.
Chambers & Partners, Germany, 2025
The lawyers are just experts. They are there when you need them and happy to entertain all my questions. They understand the wider context and the politics and sensitivities of it.
Chambers & Partners, UK 2025
Key contacts
Representative experience
Centogene on its €25m Series A financing.
Gilead Sciences on its investment on the US$120m Series B financing of AlloVir, formerly known as ViraCyte.
Gilead subsidiary, Kite Pharma, on its investment in HifiBio's US$67m Series C financing.
New Enterprise Associates on multiple equity investments, including its Series A investment in Vtesse and Series C investments in NightStarX and Mirum Pharmaceuticals.
NextCure on its IPO and in connection with several matters including its formation, US$67m Series A financing, and US$93m Series B financing.
Novartis Institutes for Biomedical Research on a number of venture capital transactions.
OncoVerity, a pioneer in applying advanced bioinformatics to drug development, on the closing of a Series A extension financing led by existing investors, argenx and RefinedScience.
Eurazeo, Bpifrance and Accel on their Series G investment in Doctolib, which, with its €5.8bn valuation, became the most valuable unicorn in the French tech sector at the time of closing.
Rice University on its launch of RBL LLC, a biotech venture creation studio developed out of the Rice Biotech Launch Pad, the university’s biotech innovation accelerator.
CatalYm GmbH, a Munich-based life sciences company, on a significant US$150m venture capital funding round.
Awards and recognitions
Band 1 for Life Sciences
Chambers Global: Multi-Jurisdictional
2022
Band 1 for Life Sciences Europe-wide
Chambers Europe
2022
Band 1 for Life Sciences in Japan
Chambers Asia-Pacific
2022
Navigate change with our latest insights
You may also be interested in...
Press releases
Hogan Lovells advises MedKitDoc on seed financing in the amount of EUR 7 million
19 January 2022
Press releases
Hogan Lovells advises MedKitDoc on seed financing in the amount of EUR 7 million
18 January 2022
Press releases
Hogan Lovells advises Engrail Therapeutics on Series A financing extension to US$64 million
04 August 2021
Press releases
Hogan Lovells advises MedKitDoc on seed financing in the amount of EUR 7 million
19 January 2022
Press releases
Hogan Lovells advises MedKitDoc on seed financing in the amount of EUR 7 million
18 January 2022
Press releases
Hogan Lovells advises Engrail Therapeutics on Series A financing extension to US$64 million
04 August 2021